Sun Pharma launches CEQUA™ (cyclosporine ophthalmic solution 0.09% w/v), the first dry eye treatment with nanomicellar (NCELL™) technology*, in Canada

Sun Pharmaceutical Industries Limited SUN HOUSE, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 CIN: L24230GJ1993PLC019050 www.sunpharma.com Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA. Reaching People. Touching Lives. FOR IMMEDIATE RELEASE Sun Pharma launches PrCEQUA™ (cyclosporine ophthalmic solution 0.09% w/v), the first dry eye treatment with nanomicellar (NCELL™) technology*, in Canada  CEQUA’s nanomicellar (NCELL) technology improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration  This technology delivers more medicine to where it’s needed most Mumbai, India & Brampton, Canada, January 27, 2022 – Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industri es Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies), today announced the launch of CEQUA, a new treatment for Canadians living with dry eye disease. CEQUA (cyclosporine ophthalmic solution 0.09% w/v), a calcineurin inhibitor immunomodulator, is the first dry eye treatment available in Canada th at is delivered with nanomicellar (NCELL) technology, which improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration. “We are excited to introduce CEQUA as a new treatm ent option for the more than six million Canadians living with dry eye disease 1,” said Abhay Gandhi, CEO North America, Sun Pharma. “This launch is an important milestone for Sun Pharma as we expand our ophthalmics portfolio into Canada and it demonstrates our commitment to providing innova tive medicines to support patient and physician choice.” In addition to its previous prevalence amongst Canadians, a recent report from Centre for Ocular Research & Education (CORE) has shown that rates of dry eye disease are on the rise due to an increase in mask wearing, which can lead to dry spots on the ocular surface.2 “We are delighted to see a new product now available to the many Canadians suffering from keratoconjunctivitis sicca or dry eye disease,” said W. Bruce Jackson, MD, former Professor and Chair, Department of Ophthalmology, McGill University and University of Ottawa. “CEQUA, with its nanomicellar technology and increased strength of cyclosporine, can be an important addition to our treatment options as eye care professionals strive for more personalized treatment.” TM - All brand names and trademarks are the property of their respective owners. * - Clinical significance unknown About CEQUA CEQUA (cyclosporine ophthalmic solution 0.09% w/ v) is a calcineurin inhibitor immunomodulator indicated to increase tear production in patients with moderate to severe keratoconjunctivitis sicca (dry eye). It uses nanomicellar technology, which penetrates the aqueous layer of the tear film in the eye and breaks up to release cyclosporine to penetrate ocular tissues. Sun Pharmaceutical Industries Limited SUN HOUSE, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 CIN: L24230GJ1993PLC019050 www.sunpharma.com Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA. Reaching People. Touching Lives. For more information visit www.sunpharma.com/canada or call 1-833-388-0532. About Dry Eye Disease Dry eye disease (keratoconjunctivitis sicca) is a diseas e affecting millions of patients around the world. According to a recent study, more than six million Canadian adults may have dry eye disease.1 Dry eye disease, as defined by the National Eye Institut e (NEI, a division of the U.S. National Institutes of Health [NIH]), occurs when the quantity and/or quality of tears fails to keep the surface of the eye properly lubricated. The disease causes a scratchy sensation or a feeling that something is in the eye. Other symptoms include stinging or burning, episod es of excess tearing following period s of stress, discharge, pain, and redness in the eye. The risk of developing dry eye increases with advancing age and is more common in women than in men.3 References: 1. Caffery, B., Srinivasan, S., Reaume, C. J., Fischer, A., Cappadocia, D., Siffel, C., Chan, C. C. (2019). Prevalence of dry eye disease in Ontario, Canada: A population-based survey. The Ocular Surface, 17(5), 526-531. https://doi.org/10.1016/j.jtos.2019.02.011 2. Charters, Lynda. COVID-19 : Masking the issue of dry eye. Ophthamology Times. Sept 2020 : https://www.ophthalmologytimes.com/view/covid-19-masking-the-issue (accessed January 25, 2020) 3. National Institutes of Health – National Eye Institute. (December 22, 2020). Dry Eye. National Eye Institute. https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/dry-eye. Disclaimer: Statements in this Document describing the Company’s objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be “forward looking statements” within the interpretations of applicable securities laws and regulations. Actu al results, performance or achievements could differ materially from those expressed or implied. The Co mpany undertakes no obligation to update or revise forward looking statements to reflect developments or ci rcumstances that arise or to reflect the occurrence of unanticipated developments or circumstances after the date hereof. About Sun Ophthalmics Backed by Sun Pharma’s global expertise in R&D, S un Ophthalmics, the branded ophthalmic division of Sun Pharma’s wholly owned subsidiary, is leading the way through the development of innovative products in partnership with eye care professionals. The company strives to deliver products built on unique platforms that integrate seamlessly into the eye care practice, helping eye care professionals to continue providing quality medicine. About Sun Pharma Canada Inc. Sun Pharmaceutical Industries Limited is growing its presence in Canada, bringing together the power of a global network with localized research and care to address the unmet needs of Canadian patients and healthcare providers. Sun Pharma Canada Inc., a wholly owned subsidiary of S un Pharmaceutical Industries Limited, is focused on providing innovative medicines in dermatology and opht halmology, bringing greater access and support for patients. Sun Pharmaceutical Industries Limited SUN HOUSE, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 CIN: L24230GJ1993PLC019050 www.sunpharma.com Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA. Reaching People. Touching Lives. Patients and healthcare providers are at the centre of everything and Sun Pharma's "passion is clear". Sun Pharma's commitment to listening, acting and caring mean s the team is able to respond to distinct needs and provide personalized care, while addressing important gaps in treatment and quality of life. Sun Pharma offers a wide range of affordable medici nes for the Canadian population. Together with Taro Pharmaceutical Industries Ltd. (a subsidiary of S un Pharma) these complementary companies bring together capabilities in specialty and niche segments coupled with a presence in the top 15 Canadian generic products. About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050) Sun Pharma is the world's fourth largest specialt y generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated busine ss and a skilled team enables it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manuf acturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural wo rkforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by stro ng R&D capabilities across multiple R&D centers, with investments of approximately 6-7% of annual reve nues in R&D. For further information, please visit www.sunpharma.com & follow us on Twitter @SunPharma_Live. Contacts: I n v e s t o r s M e d i a Nimish Desai Gaurav Chugh Tel + 91 22 4324 4324, Ext 2778 Tel + 91 22 4324 4324, Ext 5373 Tel Direct + 91 22 43242778 Tel Direct + 91 22 43245373 Mobile + 91 98203 30182 Mobile + 91 98104 71414 E mail [email protected] E mail [email protected] Canadian Media: Janet Metz Mobile +1 609-389-3044

The release as fetched from its publisher. sunpharma.com ↗